Who Is Eligible for NHS Weight Loss Injections in 2026? Full NHS Criteria Explained
Demand for NHS weight loss injections has increased significantly following recent Government announcements expanding GP involvement in obesity care.
Many patients are now asking whether they qualify for treatment through their GP — and why access remains limited despite growing availability.
Understanding NHS eligibility criteria is essential before seeking treatment.
For a full comparison of UK Mounjaro providers including pricing, see:
⇒Slinic’s Top UK Mounjaro Providers Guide
Slinic’s Prices
Our transparent pricing structure reflects the increasing strength of the medication as you progress through the treatment cycles. Each pen provides a four-week supply of weight loss injections, supported by our expert clinical team. The costs for 2026 are fixed as follows:
Mounjaro Pricing
- 2.5mg:£139
- 5mg:£165
- 7.5mg:£225
- 10mg:£255
- 12.5mg:£275
- 15mg:£285
Wegovy Pricing
For patients considering different options for medical weight loss, Wegovy remains a robust alternative with a different pricing trajectory. Understanding these figures is essential for long-term planning, especially if your clinical needs require a specific medication profile. Our Wegovy pricing for 2026 includes:
- 0.25mg:£99.99
- 0.5mg:£109.99
- 1mg:£114.99
- 1.7mg:£159.99
- 2.4mg:£209.99
Switching between different weight loss treatment options is a clinical decision that must be managed with specialist care. If you’re moving from Wegovy to Mounjaro, or vice versa, our prescribing doctors will guide you through a safe transition period. This ensures your metabolic rate remains stable while minimizing the risk of gastrointestinal discomfort. We prioritize clear escalation pathways and provide bespoke advice to ensure your transition is as tranquil as possible.
Ready to begin your journey with a specialist-led team?
NHS Weight Loss Injections Available in England
The NHS currently provides access to clinically approved weight loss medications such as tirzepatide (Mounjaro®) through a phased national rollout.
Prescribing began within general practice in 2025 and continues to expand gradually under new GP funding incentives introduced for 2026/27.
However, treatment remains prioritised for patients at highest clinical risk.
Current NHS Eligibility Criteria
To qualify for NHS weight loss injections through GP services, patients generally must meet strict medical requirements.
Patients must:
✅ Be aged 18 or over
✅ Have a Body Mass Index (BMI) of:
- 40 or higher, or
- 37.5 or higher for certain ethnic groups
AND
✅ Have multiple obesity-related health conditions, including:
- Type 2 diabetes
- High blood pressure
- Cardiovascular disease
- Obstructive sleep apnoea
- Abnormal cholesterol levels
- Severe mobility limitations
Expected Eligibility Changes From 2026
Eligibility thresholds are expected to widen slightly under the next NHS contract period:
- BMI ≥35 with four weight-related conditions
OR - BMI ≥40 with three weight-related conditions
Despite expansion, NHS treatment will continue to prioritise patients with significant medical complications first.
Why Many Patients Do Not Qualify
A large proportion of individuals seeking treatment fall outside NHS criteria.
You may not currently be eligible if:
- Your BMI is between 27–39
- You are seeking preventative treatment
- You do not yet have diagnosed medical conditions
- Local NHS prescribing pathways are not operational
This can be frustrating for patients motivated to improve their health earlier.
Alternative Access Through Clinician-Led Prescribing Clinics
While NHS services expand gradually, regulated prescribing clinics provide medically supervised treatment following clinical assessment.
At Slinic, patients undergo a full medical eligibility review conducted by qualified prescribing clinicians before treatment begins.
Patients receive:
✔ Independent prescriber assessment
✔ Evidence-based treatment planning
✔ Ongoing monitoring
✔ Lifestyle and dietary support
Start your 2 minute consultation with Slinic today>
Final Thoughts
NHS access to weight loss injections continues to expand, but eligibility remains carefully prioritised.
Understanding criteria helps patients explore appropriate treatment pathways and make informed decisions about their long-term health.
